Literature DB >> 29298144

Ofatumumab for TTP in a Patient with Anaphylaxis Associated with Rituximab.

Maeve P Crowley1, Vickie McDonald2, Marie Scully3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29298144     DOI： 10.1056/nejmc1714146

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura.

Authors:  Hanny Al-Samkari; Rachael F Grace; Jean M Connors
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

2.  Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness.

Authors:  Manuel Alfredo Podestà; Barbara Ruggiero; Giuseppe Remuzzi; Piero Ruggenenti
Journal:  BMJ Case Rep       Date:  2020-01-23

Review 3.  Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.

Authors:  Timothy M Pierpont; Candice B Limper; Kristy L Richards
Journal:  Front Oncol       Date:  2018-06-04       Impact factor: 6.244

4.  [Advances in the treatment of thrombotic thrombocytopenic purpura].

Authors:  X Y Wang; R C Yang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-12-14

5.  Refractory pemphigus vulgaris successfully treated with ofatumumab.

Authors:  Daniel M Klufas; Erin Amerson; Olivia Twu; Leon Clark; Kanade Shinkai
Journal:  JAAD Case Rep       Date:  2020-06-04

Review 6.  Pemphigus: Current and Future Therapeutic Strategies.

Authors:  Dario Didona; Roberto Maglie; Rüdiger Eming; Michael Hertl
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

Review 7.  Renal microvascular lesions in lupus nephritis.

Authors:  Ying Ding; Ying Tan; Zhen Qu; Feng Yu
Journal:  Ren Fail       Date:  2019-12-20       Impact factor: 2.606

8.  Daratumumab for immune thrombotic thrombocytopenic purpura.

Authors:  Jana van den Berg; Johanna A Kremer Hovinga; Claudia Pfleger; Inga Hegemann; Gregor Stehle; Andreas Holbro; Jan-Dirk Studt
Journal:  Blood Adv       Date:  2022-02-08

Review 9.  TTP: From empiricism for an enigmatic disease to targeted molecular therapies.

Authors:  Nuno A G Graça; Bérangère S Joly; Jan Voorberg; Karen Vanhoorelbeke; Nicolas Béranger; Agnès Veyradier; Paul Coppo
Journal:  Br J Haematol       Date:  2022-02-10       Impact factor: 8.615

Review 10.  Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase.

Authors:  John Paul Westwood; Marie Scully
Journal:  Ther Adv Hematol       Date:  2022-07-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.